Westin, J, Chavez, JC, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, García-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).

Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Piñol, JAE, Borras, JM. The precision of a report on precision. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-026-04219-6. PMID:41610006. IF:2.500(Q3/6D).

Munoz, SS, Campillo, MDE, Borrega, CS, Azeli, Y, Gil, SQ, Ruiz, A, Albacete, G, Peral, OM, Lluch, S, Delgado, SA, Blas, YS, Urra, X, Calderon, DC, Fabregas, JM, Jacobi, MR, Portela, PC, Garcia, FP, Oller, ED, Benitez, VH, Flores, A, Rubiera, M, Palomeras, E, Garcia-Tornel, A, Soler, RS, Roquet, DV, Salvat-Plana, M, Pachon, AR, Herrero, NPD, Fabrega, XJ. Prehospital care process and hospital outcomes in stroke-code cases: comparison of basic and advance life support ambulance attendance. EMERGENCIAS. 2023; 35(3)DOI:. PMID:37350599. IF:5.400(Q1/1D).

Kulisevsky, J, Ferraz, HB, Suppa, A, Reichmann, H. Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations. EUROPEAN NEUROLOGY. 2024; 87(5-6)DOI:10.1159/000541362. PMID:39342935. IF:2.400(Q3/6D).

Badia-Aguarón, T, Royuela-Colomer, E, Pera-Guardiola, V, Vergés-Balasch, P, Cebolla, A, Luciano, JV, Soler, J, Feliu-Soler, A, Miguel, AH. Combining mindfulness and cognitive training in children with attention deficit hyperactivity disorder: study protocol of a pilot randomized controlled trial (the NeuroMind study). Frontiers in Psychology. 2024; 15DOI:10.3389/fpsyg.2024.1291198. PMID:38384348. IF:2.900(Q1/3D).

Feliu-Soler, A, Royuela-Colomer, E, Navarrete, J, Jorgensen, NN, Mariño, M, Demarzo, M, Soler, J, García-Campayo, J, Montero-Marín, J, Luciano, JV. Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study. Journal of Happiness Studies. 2024; 25(7)DOI:10.1007/s10902-024-00820-0. PMID:. IF:3.300(Q1/1D).

Janssen, O, Jansen, WJ, Vos, SJB, Boada, M, Parnetti, L, Gabryelewicz, T, Fladby, T, Molinuevo, JL, Villeneuve, S, Hort, J, Epelbaum, S, Lleo, A, Engelborghs, S, van der Flier, WM, Landau, S, Popp, J, Wallin, A, Scheltens, P, Rikkert, MO, Snyder, PJ, Rowe, C, Chetelat, G, Ruiz, A, Marquie, M, Chipi, E, Wolfsgruber, S, Heneka, M, Boecker, H, Peters, O, Jarholm, J, Rami, L, Tort-Merino, A, Binette, AP, Poirier, J, Rosa-Neto, P, Cerman, J, Dubois, B, Teichmann, M, Alcolea, D, Fortea, J, Sanchez-Saudinos, MB, Ebenau, J, Pocnet, C, Eckerstrom, M, Thompson, L, Villemagne, V, Buckley, R, Burnham, S, Delarue, M, Freund-Levi, Y, Wallin, AK, Ramakers, I, Tsolaki, M, Soininen, H, Hampel, H, Spiru, L, Tijms, B, Ossenkoppele, R, Verhey, FRJ, Jessen, F, Visser, PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. ALZHEIMERS & DEMENTIA. 2022; 18(10)DOI:10.1002/alz.12512. PMID:34877782. IF:14.000(Q1/1D).

Hillerstrom, H, Fisher, R, Janicki, MP, Chicoine, B, Christian, BT, Esbensen, A, Esralew, L, Fortea, J, Hartley, S, Hassenstab, J, Keller, SM, Krinsky-McHale, S, Lai, FRC, Levin, J, Mccarron, M, Mcdade, E, Rebillat, AS, Rosas, HD, Silverman, W, Strydom, A, Zaman, SH, Zetterberg, H. Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2024; 20(5)DOI:10.1002/alz.13778. PMID:38480678. IF:11.100(Q1/1D).